Pharmaceuticals Brazil

Brazil KRAS Inhibitors Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Brazil KRAS Inhibitors Market Industry Trends and Forecast to 2034: Segmented by (Target, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Brazil · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $22.4 Mn Placeholder estimate
Estimate 2025 $30.4 Mn 2.8% of the global market
Projected 2034 $477.9 Mn 1,470.7% Adds $447.5 Mn over 9 forecast years
CAGR 2025–2034 35.8% Faster than 98% of 180 Pharmaceuticals markets here
Key players 5
  • Brazil is 2.78% of the global market.
  • In Latin America, the largest is Brazil (this report) at $30.4 Mn.
  • Fastest growing: Brazil (this report) at 35.8% a year.
  • Brazil ranks 1st of 3 by size in Latin America.

Market size projection

Brazil

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$447.5 Mn total, 2026–2034

Year-by-year market size, 2024–2034
KRAS Inhibitors Market market size by year, Brazil
YearMarket sizeChange that yearSince 2025
2024 (estimate) $22.4 Mn — —
2025 (base) $30.4 Mn +$8.0 Mn —
2026 (forecast) $41.3 Mn +$10.9 Mn +35.8%
2027 (forecast) $56.1 Mn +$14.8 Mn +84.4%
2028 (forecast) $76.2 Mn +$20.1 Mn +150.4%
2029 (forecast) $103.5 Mn +$27.3 Mn +240.1%
2030 (forecast) $140.5 Mn +$37.0 Mn +361.8%
2031 (forecast) $190.8 Mn +$50.3 Mn +527.2%
2032 (forecast) $259.2 Mn +$68.3 Mn +751.7%
2033 (forecast) $352.0 Mn +$92.8 Mn +1,056.6%
2034 (forecast) $477.9 Mn +$126.0 Mn +1,470.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Brazil KRAS Inhibitors Market Analysis at a glance
Market size, 2025$30.4 Mn placeholder estimate
Forecast, 2034$477.9 Mn placeholder estimate
Growth (CAGR), 2025–203435.8% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTarget, indication and end user (see all)
Key playersAmgen Inc., Bristol-Myers Squibb, Eli Lilly and Company, Revolution Medicines, Novartis AG (see all)
Regulator in BrazilANVISASource: ANVISA. Checked 14 Nov 2026.
Active clinical trials28 in BrazilSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Brazil. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Brazil KRAS Inhibitors Market Analysis Executive Summary

KRAS inhibitors target a common cancer-causing gene mutation that was long thought impossible to drug, mainly in lung and bowel cancers.

Key segments of the KRAS Inhibitors market include target (KRAS G12C, KRAS G12D and Pan-KRAS) and indication (Non-Small Cell Lung Cancer, Colorectal Cancer and Pancreatic Cancer).

Bar chart: Brazil KRAS Inhibitors market size, 2024–2034, placeholder estimates. $22.4 Mn in 2024, $30.4 Mn in 2025 and $477.9 Mn in 2034, 35.8% CAGR.
Brazil KRAS Inhibitors market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Brazil KRAS Inhibitors Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the KRAS Inhibitors market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the KRAS Inhibitors market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the KRAS Inhibitors market, especially in low- and middle-income countries.

Competitive Landscape for KRAS Inhibitors Market in Brazil

The KRAS Inhibitors market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for KRAS Inhibitors Market in Brazil

KRAS Inhibitors in Brazil: rules, payment and research

Medicines need registration with ANVISA, the National Health Surveillance Agency, before sale.⁠[1] The Unified Health System (SUS) gives free public care to everyone, and CONITEC advises which medicines and technologies it adds.⁠[2] ClinicalTrials.gov lists 28 studies on KRAS Inhibitors that are recruiting, active or about to start in Brazil.⁠[3]

[1] ANVISA. Checked 14 Nov 2026.

[2] CONITEC. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Brazil. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for KRAS Inhibitors. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Brazil.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in KRAS Inhibitors right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

KRAS Inhibitors in context

Brazil compared

  • Health spending per person: 1,010 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 4 countries we cover in Latin America.[1]
  • Doctors: 2.36 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 2nd highest of the 4 countries we cover in Latin America.[2]
  • People aged 65 and over: 11.5% of people (2025). World: 10.4% of people (2025). Highest of the 4 countries we cover in Latin America.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 16 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the KRAS Inhibitors market in Brazil?
Placeholder estimate: about $30.4 Mn in 2025, rising to about $477.9 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the KRAS Inhibitors market in Brazil growing?
Placeholder estimate: about 35.8% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the KRAS Inhibitors market report cover?
The report splits the market by target (KRAS G12C, KRAS G12D, Pan-KRAS), indication (Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the KRAS Inhibitors market?
Key players include Amgen Inc., Bristol-Myers Squibb, Eli Lilly and Company, Revolution Medicines and Novartis AG.
What is driving the KRAS Inhibitors market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the KRAS Inhibitors market. Faster approvals and new combinations are improving survival.
Who regulates KRAS Inhibitors in Brazil?
Medicines need registration with ANVISA, the National Health Surveillance Agency, before sale. Source: ANVISA. Checked 14 Nov 2026.
How is healthcare paid for in Brazil?
The Unified Health System (SUS) gives free public care to everyone, and CONITEC advises which medicines and technologies it adds. Source: CONITEC. Checked 14 Nov 2026.
How many clinical trials on KRAS Inhibitors are running in Brazil?
28 studies are recruiting, active or about to start in Brazil, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Brazil. Retrieved 12 Nov 2026.
How much research is published on KRAS Inhibitors?
PubMed lists 440 papers on KRAS Inhibitors added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Brazil

See all

Related on oncology

See the topic